SynthesisJournal of clinical gastroenterology2015
Use of Biologics in Pouchitis: A Systematic Review.
Synthesis in Journal of clinical gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.The Cochrane database of systematic reviews · 2019Pooled it
- Managing Refractory Pouchitis: Which Biologic Is Best?Digestive diseases and sciences · 2026Article
- A Pilot Study of the Effectiveness and Safety of Subcutaneous Infliximab in Chronic Inflammatory Pouch Conditions: The St. Mark's Experience.Journal of clinical medicine · 2026Article
- Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn's Disease of the Pouch.Inflammatory bowel diseases · 2025Article
- Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study.Biomedicines · 2025Article
- Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review.Iranian journal of medical sciences · 2024Review
- Comprehensive systematic review and pooled analysis of real-world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry.Crohn's & colitis 360 · 2022Article
- Pouchitis: insight into the pathogenesis and clinical aspects.American journal of translational research · 2022Review
- A case of refractory pouchitis complicated by cytomegalovirus infection requiring administration of ganciclovir and infliximab.Clinical journal of gastroenterology · 2021Article
- Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment.Intestinal research · 2021Review
- Medical treatment of pouchitis: a guide for the clinician.Therapeutic advances in gastroenterology · 2021Review
- A case of refractory chronic pouchitis successfully treated with tofacitinib.Clinical journal of gastroenterology · 2020Article
- Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States.Crohn's & colitis 360 · 2020Article
- Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report.World journal of clinical cases · 2019Article
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.The Cochrane database of systematic reviews · 2019Article
- Vedolizumab for chronic antibiotic-refractory pouchitis.Gastroenterology report · 2019Article
- Infliximab in inflammatory bowel disease.Therapeutic advances in chronic disease · 2019Review
- Outcomes and Management of the Ileal Pouch-Anal Anastomosis in the Elderly.Current treatment options in gastroenterology · 2018Review
- Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study.Journal of gastroenterology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Data about the effectiveness of biologics, including anti-tumor necrosis factor (TNF) therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn's disease-associated pouch complications are sparse. We performed a systematic review of the literature in Medline and Web of Science. All English language publications and meeting abstracts describing patients with pouchitis treated with anti-TNF or anti-integrin therapies were included. We identified a total of 17 papers and 2 abstracts, most of these retrospective case series, including a total of 192 patients treated either with infliximab (n=140) or adalimumab (n=52). No reports were found for anti-integrin therapies or other anti-TNF agents such as certolizumab pegol or golimumab. Because of the heterogeneity of the studies, small numbers of patients, differing cotreatments, and subjective outcome definitions, the exact efficacy of these biological therapies cannot be assessed in a combined fashion. Overall infliximab appears to have good clinical effectiveness in selected patients achieving up to 80% short-term and around 50% long-term response, whereas the few data available for adalimumab are not sufficient to draw valid conclusions. Larger prospectively collected multicenter data with clearly defined inclusion criteria and outcomes are necessary to better define the clinical value of anti-TNF therapy in patients with antibiotic refractory pouchitis or Crohn's-like complications of the pouch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.